HC Wainwright began coverage on shares of Cyclo Therapeutics (NASDAQ:CYTH – Free Report) in a research note published on Wednesday, Marketbeat Ratings reports. The firm issued a buy rating and a $3.00 price target on the stock. HC Wainwright also issued estimates for Cyclo Therapeutics’ Q1 2024 earnings at ($0.20) EPS, Q2 2024 earnings at […]